Immix Biopharma (NASDAQ: IMMX) net income
Immix Biopharma reported a net loss of $29.4m for fiscal 2025; in fiscal 2024 it reported a net loss of $21.6m. Earnings per share were −$0.89.
Immix Biopharma's best year of the last 6 was fiscal 2020. It reported a loss in 6 of those 6 years.
Embed this chart
Copy this code into your website or blog. The chart updates with each new annual report.
Net income by fiscal year
| Fiscal year | Net income | Change | Net margin | Earnings per share |
|---|---|---|---|---|
| 2025 | −$29.4m | — | — | −$0.89 |
| 2024 | −$21.6m | — | — | −$0.76 |
| 2023 | −$15.4m | — | — | −$0.89 |
| 2022 | −$8.2m | — | — | −$0.59 |
| 2021 | −$24.4m | — | — | −$6.64 |
| 2020 | −$1.1m | — | — | — |
The change compares each fiscal year with the one before and is not calculated when the previous year closed with a loss. Net margin is net income over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.
Immix Biopharma net income compared with its sector
By net income for its latest fiscal year, Immix Biopharma ranks 223rd of the 501 US health care companies with a page on Celsmar.
| Rank | Company | Net income | Net margin |
|---|---|---|---|
| 221st | SELLAS Life Sciences Group | −$26.9m | — |
| 222nd | Weave Communications | −$28.1m | −11.7% |
| 223rd | Immix Biopharma | −$29.4m | — |
| 224th | Galectin Therapeutics | −$30.8m | — |
| 225th | DiaMedica Therapeutics | −$32.8m | — |
Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.
Questions about the net income of Immix Biopharma
- How much did Immix Biopharma earn in fiscal 2025?
- Immix Biopharma reported a net loss of $29.4m for fiscal 2025. In fiscal 2024 it reported a net loss of $21.6m.
- What are the earnings per share of Immix Biopharma?
- They were −$0.89 in fiscal 2025, compared with −$0.76 in fiscal 2024.
- Where does Immix Biopharma rank in its sector by net income?
- It ranks 223rd of the 501 US health care companies with a page on Celsmar, by net income for its latest fiscal year.
- Where do the figures for Immix Biopharma come from?
- From the annual report (Form 10-K) that Immix Biopharma files with the SEC, the US securities regulator. Each fiscal year links to its filing.
Where each figure comes from
From the annual report (Form 10-K) that Immix Biopharma files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021 · 2020. More on Immix Biopharma: the Immix Biopharma page · annual accounts · insider transactions.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.